<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03582449</url>
  </required_header>
  <id_info>
    <org_study_id>SHP ELA-701</org_study_id>
    <nct_id>NCT03582449</nct_id>
  </id_info>
  <brief_title>Intensive Pharmacovigilance Program for Elaprase (SHP ELA-701)</brief_title>
  <official_title>Intensive Pharmacovigilance Program for Elaprase (SHP ELA-701)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this non-interventional, observational study which is conducted in Mexico is&#xD;
      to evaluate the safety profile of elaprase (idulsurfase) in participants with hunter syndrome&#xD;
      (mucopolysaccharydosis II) being treated with elaprase.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 19, 2018</start_date>
  <completion_date type="Actual">May 10, 2020</completion_date>
  <primary_completion_date type="Actual">May 10, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events During Administration of Elaprase</measure>
    <time_frame>During 12 months of study participation</time_frame>
    <description>An adverse event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered as a pharmaceutical product that do not necessarily have a causal relationship with this treatment. Incidence of adverse events during administration of elaprase will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Events According to the System Organ Class and MedDRA Preferred Term</measure>
    <time_frame>During 12 months of study participation</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a clinical investigation participant administered as a pharmaceutical product that do not necessarily have a causal relationship with this treatment. Incidence of adverse events according to the system organ class and MedDRA preferred term will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Events 2 months After Early Termination of Elaprase Treatment.</measure>
    <time_frame>2 months after early termination of Elaprase treatment</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a clinical investigation participant administered as a pharmaceutical product that do not necessarily have a causal relationship with this treatment. Incidence of adverse events 2 months after early termination of Elaprase treatment will be reported.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Height Over One Year Study Period</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Change in height over one year study period will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Weight Over One Year Study Period</measure>
    <time_frame>Baseline, 12 months</time_frame>
    <description>Change in weight over one year study period will be assessed.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">5</enrollment>
  <condition>Hunter Syndrome</condition>
  <arm_group>
    <arm_group_label>Elaprase</arm_group_label>
    <description>Participants with Hunter syndrome (Mucopolysaccharydosis II) being treated with Elaprase will be evaluated for this study.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with hunter syndrome (mucopolysaccharydosis II) being treated with elaprase&#xD;
        will be evaluated for this study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants of both genders&#xD;
&#xD;
          -  Participants to whom idursulfase (Elaprase) has been prescribed&#xD;
&#xD;
          -  Participants with Hunter syndrome&#xD;
&#xD;
          -  Participants accepting to participate&#xD;
&#xD;
          -  Participants signing the informed consent and privacy notice for handling personal&#xD;
             information in: the program Contigo Shire (training, diagnosis, family trees) and the&#xD;
             intensive pharmacovigilance study for Elaprase. If the participant is unable to&#xD;
             provide legal consent (example: under legal age), the participant's legal guardian&#xD;
             must provide consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants withdrawing their consent to continue participating in the&#xD;
             non-intervention intensive pharmacovigilance study for Elaprase&#xD;
&#xD;
          -  Known hypersensitivity or presence of any contraindication to Elaprase that cannot be&#xD;
             controlled by pre-medication&#xD;
&#xD;
          -  A physical condition that would not permit intravenous administration of enzyme&#xD;
             replacement therapy (ERT)&#xD;
&#xD;
          -  Participants enrolled in Shire sponsored Elaprase Registry or any other Shire&#xD;
             sponsored Elaprase study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shire Study Physician</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Pediátrico de Sinaloa</name>
      <address>
        <city>Culiacán Rosales</city>
        <state>México</state>
        <zip>80200</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IMSS UMAE 25 (INSTITUTO MEXICANO DEL SEGURO SOCIAL UNIDAD MEDICA DE ALTA ESPECIALIDAD No 25)</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <zip>64180</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Niño Tabasqueño</name>
      <address>
        <city>Villahermosa</city>
        <state>Tabasco</state>
        <zip>86100</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Centenario Miguel Hidalgo</name>
      <address>
        <city>Aguascalientes</city>
        <zip>CP 20000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Infantil Federico Gomez</name>
      <address>
        <city>Ciudad de México</city>
        <zip>06720</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Colima</name>
      <address>
        <city>Colima</city>
        <zip>28019</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.takeda.com/study-detail/5f6b5fd24db2bf003ab46ab5</url>
    <description>To obtain more information on the study, click here/on this link</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>June 28, 2018</study_first_submitted>
  <study_first_submitted_qc>June 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 11, 2018</study_first_posted>
  <last_update_submitted>February 25, 2021</last_update_submitted>
  <last_update_submitted_qc>February 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hunter syndrome (Mucopolysaccharydosis II)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mucopolysaccharidosis II</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/takeda/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

